Caseware UK (AP4) 2023.0.135 2023.0.135 2024-03-312024-03-3102023-04-01falsespecialist medical consultant0truetrueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006. 10137327 2023-04-01 2024-03-31 10137327 2022-04-01 2023-03-31 10137327 2024-03-31 10137327 2023-03-31 10137327 c:Director1 2023-04-01 2024-03-31 10137327 d:FurnitureFittings 2023-04-01 2024-03-31 10137327 d:FurnitureFittings 2024-03-31 10137327 d:FurnitureFittings 2023-03-31 10137327 d:FurnitureFittings d:OwnedOrFreeholdAssets 2023-04-01 2024-03-31 10137327 d:CurrentFinancialInstruments 2024-03-31 10137327 d:CurrentFinancialInstruments 2023-03-31 10137327 d:CurrentFinancialInstruments d:WithinOneYear 2024-03-31 10137327 d:CurrentFinancialInstruments d:WithinOneYear 2023-03-31 10137327 d:ShareCapital 2024-03-31 10137327 d:ShareCapital 2023-03-31 10137327 d:RetainedEarningsAccumulatedLosses 2024-03-31 10137327 d:RetainedEarningsAccumulatedLosses 2023-03-31 10137327 d:FinancialAssetsDesignatedFairValueThroughProfitOrLoss 2024-03-31 10137327 d:FinancialAssetsDesignatedFairValueThroughProfitOrLoss 2023-03-31 10137327 c:FRS102 2023-04-01 2024-03-31 10137327 c:AuditExempt-NoAccountantsReport 2023-04-01 2024-03-31 10137327 c:FullAccounts 2023-04-01 2024-03-31 10137327 c:PrivateLimitedCompanyLtd 2023-04-01 2024-03-31 10137327 e:PoundSterling 2023-04-01 2024-03-31 iso4217:GBP xbrli:pure

Registered number: 10137327









WESSEX UROLOGY LIMITED







UNAUDITED

FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2024

 
WESSEX UROLOGY LIMITED
REGISTERED NUMBER: 10137327

BALANCE SHEET
AS AT 31 MARCH 2024

2024
2023
Note
£
£

Fixed assets
  

Tangible assets
 4 
438
584

  
438
584

Current assets
  

Debtors: amounts falling due within one year
 5 
11,951
46,694

Cash at bank and in hand
 6 
233,664
214,411

  
245,615
261,105

Creditors: amounts falling due within one year
 7 
(12,215)
(37,077)

Net current assets
  
 
 
233,400
 
 
224,028

Total assets less current liabilities
  
233,838
224,612

  

Net assets
  
233,838
224,612


Capital and reserves
  

Called up share capital 
  
100
100

Profit and loss account
  
233,738
224,512

  
233,838
224,612


Page 1

 
WESSEX UROLOGY LIMITED
REGISTERED NUMBER: 10137327
    
BALANCE SHEET (CONTINUED)
AS AT 31 MARCH 2024

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 28 January 2025.





................................................
Dr Melissa Clare Davies
Director


The notes on pages 3 to 8 form part of these financial statements.

Page 2

 
WESSEX UROLOGY LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

1.


General information

Wessex Urology Limited is a private company limited by shares, incorporated in England and Wales. The principal activity throughout the year was that of a specialist medical consultant. 

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The following principal accounting policies have been applied:

 
2.2

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

 
2.3

Finance costs

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

 
2.4

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

Page 3

 
WESSEX UROLOGY LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

2.Accounting policies (continued)

 
2.5

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, on a reducing balance basis.

Depreciation is provided on the following basis:

Fixtures and fittings
-
25%
reducing balance

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.6

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.7

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.8

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

Page 4

 
WESSEX UROLOGY LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

2.Accounting policies (continued)

 
2.9

Financial instruments

The Company has elected to apply the provisions of Section 11 “Basic Financial Instruments” of FRS 102 to all of its financial instruments.

Basic financial assets

Basic financial assets, which include trade and other receivables, cash and bank balances, are initially measured at their transaction price including transaction costs and are subsequently carried at their amortised cost using the effective interest method, less any provision for impairment, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

Discounting is omitted where the effect of discounting is immaterial. The Company's cash and cash equivalents, trade and most other receivables due with the operating cycle fall into this category of financial instruments.

Financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instruments any contract that evidences a residual interest in the assets of the Company after the deduction of all its liabilities.

Basic financial liabilities, which include trade and other payables, bank loans and other loans are initially measured at their transaction price after transaction costs. When this constitutes a financing transaction, whereby the debt instrument is measured at the present value of the future receipts discounted at a market rate of interest. Discounting is omitted where the effect of discounting is immaterial.

Debt instruments are subsequently carried at their amortised cost using the effective interest rate method.

Trade payables are obligations to pay for goods and services that have been acquired in the ordinary course of business from suppliers. Trade payables are classified as current liabilities if the payment is due within one year. If not, they represent non-current liabilities. Trade payables are initially recognised at their transaction price and subsequently are measured at amortised cost using the effective interest method. Discounting is omitted where the effect of discounting is immaterial.

 
2.10

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.


3.


Employees




The Company has no employees other than the directors, who did not receive any remuneration (2023 - £Nil).

Page 5

 
WESSEX UROLOGY LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

4.


Tangible fixed assets





Fixtures and fittings

£



Cost or valuation


At 1 April 2023
1,096



At 31 March 2024

1,096



Depreciation


At 1 April 2023
512


Charge for the year on owned assets
146



At 31 March 2024

658



Net book value



At 31 March 2024
438



At 31 March 2023
584

Page 6

 
WESSEX UROLOGY LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

5.


Debtors

2024
2023
£
£


Trade debtors
11,951
16,694

Other debtors
-
30,000

11,951
46,694



6.


Cash and cash equivalents

2024
2023
£
£

Cash at bank and in hand
233,664
214,411

233,664
214,411



7.


Creditors: Amounts falling due within one year

2024
2023
£
£

Corporation tax
9,815
13,075

Other creditors
1,020
22,682

Accruals and deferred income
1,380
1,320

12,215
37,077


Included within other creditors is an amount of £1,020 (2023 - £22,682) owed to the directors, Dr Melissa Clare Davies and Ryan Howard.


8.


Financial instruments

2024
2023
£
£

Financial assets


Financial assets measured at fair value through profit or loss
233,664
214,411




Financial assets measured at fair value through profit or loss comprise cash at bank and in hand.

Page 7

 
WESSEX UROLOGY LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

9.


Controlling party

The Company is controlled by the directors, Dr Melissa Clare Davies and Ryan Howard, by virtue of their shareholdings as described in the directors' report.

 
Page 8